Myriad to Announce Fiscal Third-Quarter 2018 Financial Results on May 8, 2018
April 17 2018 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced that it will
hold its fiscal third-quarter 2018 sales and earnings conference
call with investors and analysts at 7:30 a.m. ET on Tuesday, May 8,
2018. During the call, Mark C. Capone, president and CEO and
Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial
performance for the fiscal third-quarter and provide a business
update. Additionally, Dr. Bryan Dechairo, executive vice president
of Clinical Research, will discuss the data from the GeneSight
randomized controlled trial. The clinical study data will first be
presented as a late breaking poster in the exhibit hall at the
American Psychiatric Association annual meeting on Monday, May 7,
2018 at 10:00 a.m. ET, and will be presented by the study principal
investigator the same day at a satellite symposium at 6:30 p.m. ET
at Hudson Mercantile at 500 W. 36th Street in New York City.
To listen to the earnings call, interested parties in the United
States may dial 800-699-0623 or +1 303-223-4362 for international
callers. All callers will be asked to reference reservation
number 21887258. The conference call also will be available through
a live webcast and a slide presentation pertaining to the earnings
call will also be available under the investor section of our
website at www.myriad.com. A replay of the call will be
available two hours after the end of the call for seven days and
may be accessed by dialing 800-633-8284 within the United States or
+1 402-977-9140 for international callers and entering reservation
number 21887258.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: building upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
Media
Contact: |
|
Ron
Rogers(801) 584-3065rrogers@myriad.com |
|
Investor
Contact: |
|
Scott
Gleason(801) 584-1143sgleason@myriad.com |
|
|
|
|
|
|
|
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024